Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 11, 2004, Pages 4473-4475

  Gurumurthy, Prema ^a,c   Ramachandran, Geetha ^a   Hemanth Kumar, A K ^a   Rajasekaran, S ^b   Padmapriyadarsini, C ^a   Swaminathan, Soumya ^a   Bhagavathy, S ^a   Venkatesan, P ^a   Sekar, L ^a   Mahilmaran, A ^b   Ravichandran, N ^b   Paramesh, P ^b  

^a INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

^b GOVERNMENT GENERAL HOSPITAL   (India)

^c KJ Hosp Post Grad/Res Found   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ACETYLATOR PHENOTYPE; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CRYPTOSPORIDIOSIS; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG URINE LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MAXIMUM PLASMA CONCENTRATION; PARAMETER; PRIORITY JOURNAL; RAPID ACETYLATOR PHENOTYPE; TIME TO REACH PEAK PLASMA CONCENTRATION;

ACETYLATION; ADULT; ANTIBIOTICS, ANTITUBERCULAR; ANTITUBERCULAR AGENTS; BIOLOGICAL AVAILABILITY; ETHAMBUTOL; FECES; FEMALE; HIV INFECTIONS; HUMANS; INTESTINAL ABSORPTION; ISONIAZID; MALE; MIDDLE AGED; PHENOTYPE; PYRAZINAMIDE; RIFAMPIN; TUBERCULOSIS;

EID: 7244231217     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.11.4473-4475.2004     Document Type: Article

References (19)

1. Acocella, G., A. Nonis, G. Perna, E. Patane, G. Gialdroni-Grassi, and C. Grassi. 1988. Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. Am. Rev. Respir. Dis. 138:886-890.
2. Barakat, M. T., J. Scott, J. M. Hughes, M. Walport, J. Calam, J. S. Friedland, P. W. Ind, and C. McKenna. 1996. Persistent fever in pulmonary tuberculosis (clinical conference). Br. Med. J. 313:1543-1545.
3. Berning, S. E., G. A. Huitt, M. D. Iseman, and C. A. Peloquin. 1992. Malabsorption of antituberculosis medications by a patient with AIDS. N. Engl. J. Med. 327:1817-1818.
4. Choudhri, S. H., M. Hawken, S. Gathua, G. O. Minyiri, W. Watkins, J. Sahai, D. S. Sitar, F. Y. Aoki, and R. Long. 1997. Pharmacokinetics of antimycobacterial drugs in patients with tuberculosis, AIDS, and diarrhea. Clin. Infect. Dis. 25:104-111.
5. Ellard, G. A., D. R. Ellard, B. W. Allen, D. J. Girling, A. J. Nunn, S. K. Teo, H. K. Ng, and S. L. Chan. 1986. The bioavailability of isoniazid, rifampin, and pyrazinamide in two commercially available combined formulations designed for use in the short-course treatment of tuberculosis. Am. Rev. Respir. Dis. 133:1076-1080.
6. Gordon, S. M., C. R. Horsburgh, Jr., C. A. Peloquin, J. A. Havlik, Jr., B. Metchock, L. Heifets, J. E. McGowan, Jr., and S. E. Thompson III. 1993. Low serum levels of oral antimycobacterial agents in patients with disseminated Mycobacterium avium complex disease. J. Infect. Dis. 168:1559-1562.
7. Gurumurthy, P., G. Ramachandran, A. K. Hemanth Kumar, S. Rajasekaran, C. Padmapriyadarsini, S. Swaminathan, P. Venkatesan, L. Sekar, S. Kumar, O. R. Krishnarajasekhar, and P. Paramesh. 2004. Malabsorption of rifampicin and isoniazid in HIV infected patients with and without tuberculosis. Clin. Infect. Dis. 38:280-283.
8. Gurumurthy, P., T. N. Gayathri, S. Bhagavathy, and P. Venkatesan. 2004. Standardisation of the method for the estimation of ethambutol in pharmaceutical preparations and in biological fluid. Ind. J. Exp. Biol. 42:68-73.
9. Gurumurthy, P., N. G. K. Nair, and G. Raghupati Sarma. 1980. Methods for the estimation of pyrazinamide and pyrazinoic acid in body fluids. Ind. J. Med. Res. 71:129-134.
10. Hemanth Kumar, A. K., C. Immanuel, G. Ramachandran, K. Silambu Chelvi, L. Victor, and P. Gurumurthy. 2004. A validated high performance liquid chromatography method for the determination of rifampicin and desacetyl rifampicin in plasma and urine. Ind. J. Pharmacol.
11. Kotler, D. P., A. Francisco, F. Clayton, J. V. Scholes, and J. M. Orenstein. 1990. Small intestinal injury and parasitic diseases in AIDS. Ann. Intern. Med. 113:444-449.
12. Olson, W. A., P. G. Dayton, Z. H. Israili, and A. W. Pruitt. 1977. Spectrophotofluorimetric assay for isoniazid and acetylisoniazid in plasma adapted to paediatric studies. Clin. Chem. 23:745-748.
13. Patel, K. B., R. Belmonte, and H. M. Crowe. 1995. Drug malabsorption and resistant tuberculosis in HIV-infected patients. N. Engl. J. Med. 332:336-337.
14. Peloquin, C. A., A. A. MacPhee, and S. E. Berning. 1993. Malabsorption of antimycobacterial medications. N. Engl. J. Med. 329:1122-1123.
15. Peloquin, C. A., A. T. Nitta, W. J. Burman, K. F. Brudney, J. R. Miranda-Massari, M. E. McGuinness, S. E. Berning, and G. T. Gerena. 1996. Low antituberculosis drug concentrations in patients with AIDS. Ann. Pharmacother. 30:919-923.
16. Raghupati Sarma, G., M. Kannapiran, A. S. L. Narayana, S. Radhakrishna, and S. P. Tripathy. 1976. Determination of acetylator phenotype based on the ratio of acetylisoniazid to isoniazid in urine following an oral dose of ordinary isoniazid. Ind. J. Med. Res. 64:1-8.
17. Sahai, J., K. Gallicano, L. Swick, S. Tailor, G. Garber, I. Seguin, L. Oliveras, S. Walker, A. Rachlis, and D. W. Cameron. 1997. Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. Ann. Intern. Med. 127:289-293.
18. Small, P. M., G. F. Schecter, P. C. Goodman, M. A. Sande, R. E. Chaisson, and P. C. Hopewell. 1991. Treatment of tuberculosis in patients with advanced human immune-deficiency virus infection. N. Engl. J. Med. 324:289-294.
19. Taylor, B., and P. J. Smith. 1998. Does AIDS impair the absorption of antituberculosis agents? Int. J. Tuberc. Lung Dis. 2:670-675.